| Filed On | Filing |
|---|---|
| 22 Oct 2026 |
8-K: Regulation FD Disclosure
On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program. |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. Excluded information ... |
| 17 Sep 2026 |
Form 4: Gentile Kimberly, SVP, Clinical Operations
Granted 1,000 Stock Options (Right to buy) |
| 10 Sep 2026 |
8-K: Other Events
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. |
| 26 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure |
| 14 Aug 2026 |
Form 3: Yetimoglu John, Director
Holds 6,250,000 shares of Common Shares |
| 14 Aug 2026 | SCHEDULE 13G |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 07 Aug 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 17 Jul 2026 |
Form 3: Volles Warren Karl, Chief Legal Officer
Holds 248,212 shares of Common Shares |
| 09 Jul 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 08 Jul 2026 | SCHEDULE 13G/A |
| 27 May 2026 | 8-K: Regulation FD Disclosure |
| 15 May 2026 | SCHEDULE 13G/A |
| 05 May 2026 | 8-K: Other Events |
| 04 May 2026 | 424B5 |
| 04 May 2026 | S-3ASR |
| 04 May 2026 | 10-Q |
| 04 May 2026 | 8-K: Results of Operations and Financial Condition |
Loading...
